BRPI0518829A2 - mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas - Google Patents

mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas

Info

Publication number
BRPI0518829A2
BRPI0518829A2 BRPI0518829-6A BRPI0518829A BRPI0518829A2 BR PI0518829 A2 BRPI0518829 A2 BR PI0518829A2 BR PI0518829 A BRPI0518829 A BR PI0518829A BR PI0518829 A2 BRPI0518829 A2 BR PI0518829A2
Authority
BR
Brazil
Prior art keywords
treatment
neuropathic pain
associated syndromes
syndromes
ibudilast
Prior art date
Application number
BRPI0518829-6A
Other languages
English (en)
Inventor
Kirk W Johnson
Lance Sultzbaugh
Jennifer Shumilla
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Publication of BRPI0518829A2 publication Critical patent/BRPI0518829A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

MÉTODO PARA O TRATAMENTO DE DOR NEUROPÁTICA E SINDROMES ASSOCIADAS. A presente invenção é dirigida ao uso de ibudilast para o tratamento de dor neuropática.
BRPI0518829-6A 2004-12-06 2005-12-06 mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas BRPI0518829A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63424804P 2004-12-06 2004-12-06
US66527605P 2005-03-25 2005-03-25
US71633305P 2005-09-12 2005-09-12
PCT/US2005/044258 WO2006063048A2 (en) 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes

Publications (1)

Publication Number Publication Date
BRPI0518829A2 true BRPI0518829A2 (pt) 2008-12-09

Family

ID=36476178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518829-6A BRPI0518829A2 (pt) 2004-12-06 2005-12-06 mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas

Country Status (8)

Country Link
US (2) US7534806B2 (pt)
EP (1) EP1835913A2 (pt)
JP (2) JP4954085B2 (pt)
AU (1) AU2005314133B2 (pt)
BR (1) BRPI0518829A2 (pt)
CA (1) CA2587791C (pt)
MX (1) MX2007006777A (pt)
WO (1) WO2006063048A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1928438T3 (da) * 2005-09-26 2013-04-22 Avigen Inc Anvendelse af ibudilast til behandling af stofafhængighed
US20070191365A1 (en) * 2006-01-13 2007-08-16 Lance Sultzbaugh 3,4,6-Substituted pyridazines for treating neuropathic pain and associated syndromes
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
CA2669463A1 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
BRPI0814624A2 (pt) 2007-07-11 2015-01-27 Medicinova Inc Tratamento de doença neurodegenerativa progresiva com ibudilaste
US20090028816A1 (en) * 2007-07-27 2009-01-29 Lance Sultzbaugh Treatment of depression, psychosis, and anxiety
WO2011127586A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
RU2459642C2 (ru) * 2010-04-27 2012-08-27 Министерство обороны Российской Федерации, Государственное образовательное учреждение высшего профессионального образования Военно-медицинская академия им. С.М. Кирова (ВМедА) Способ лечения травматических невропатий
NZ605887A (en) * 2010-08-04 2014-08-29 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
EP4186501A1 (en) * 2011-04-27 2023-05-31 Yale University, Inc. Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits
WO2016081022A1 (en) * 2014-11-18 2016-05-26 PixarBio Corporation Compositions for treating acute, post-operative, or chronic pain and methods of using the same
WO2016085998A1 (en) 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
EP3488220A4 (en) * 2016-11-29 2020-03-04 Axim Biotechnologies, Inc. CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND NICOTINE
EP3558301A4 (en) 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
CA3090884A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
WO2020076809A1 (en) 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
WO2020081941A1 (en) 2018-10-19 2020-04-23 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
US20220347159A1 (en) * 2019-06-11 2022-11-03 Yale University Novel treatment for wolfram syndrome
WO2021061554A1 (en) 2019-09-23 2021-04-01 Medicinova, Inc. Ibudilast oral formulations and methods of using same
WO2021207054A1 (en) 2020-04-06 2021-10-14 Medicinova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
CA3206115A1 (en) 2021-01-29 2022-08-04 Kazuko Matsuda Methods of treating chemical gas exposure
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
CA3231869A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US20230285367A1 (en) 2022-02-01 2023-09-14 Medicinova, Inc. Methods of treating post-covid condition(s)
US20240016729A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263520A (ja) 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
ATE283047T1 (de) * 1998-08-10 2004-12-15 Kyorin Seiyaku Kk Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose
EP1106210A3 (en) 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US7135495B2 (en) 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
AU2001244618A1 (en) * 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
AU2001257591A1 (en) 2000-03-31 2001-10-15 Biogen, Inc. Methods of identifying integrin ligands using differential gene expression
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
CA2422342C (en) 2000-09-14 2009-12-08 Mitsubishi Pharma Corporation Novel amide derivatives and medicinal use thereof
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
EP1348443A4 (en) 2000-12-08 2005-07-06 Takeda Pharmaceutical COMBINED MEDICINES
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002098429A1 (en) 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
WO2002100433A1 (en) 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
EP1411934A1 (en) * 2001-07-31 2004-04-28 PHARMACIA & UPJOHN COMPANY Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines
WO2003013513A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Stable emulsion composition
WO2003014110A1 (fr) 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Derive de benzazepine, son procede de preparation et d'utilisation
CA2457482A1 (en) 2001-08-09 2003-02-27 Kissei Pharmaceutical Co., Ltd. 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
US7153852B2 (en) 2001-09-07 2006-12-26 Ono Pharmaceutical Co., Ltd. Indole compounds, process for producing the same and drugs containing the same as the active ingredient
EP1424335A4 (en) 2001-09-07 2005-11-16 Ono Pharmaceutical Co INDOLE DERIVATIVES
JPWO2003040086A1 (ja) 2001-11-09 2005-03-03 キッセイ薬品工業株式会社 ５−アミジノ−２−ヒドロキシベンゼンスルホンアミド誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
US20050245537A1 (en) 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
AU2003241326B2 (en) 2002-05-02 2008-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
CA2503715A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20060083714A1 (en) 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
EP1603933A2 (en) 2003-03-13 2005-12-14 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DE602004031356D1 (de) 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
US20060160843A1 (en) 2006-07-20
JP2008013577A (ja) 2008-01-24
WO2006063048A2 (en) 2006-06-15
US7534806B2 (en) 2009-05-19
JP4954085B2 (ja) 2012-06-13
CA2587791A1 (en) 2006-06-15
AU2005314133B2 (en) 2012-03-08
EP1835913A2 (en) 2007-09-26
JP2008522979A (ja) 2008-07-03
CA2587791C (en) 2012-03-13
MX2007006777A (es) 2007-08-06
AU2005314133A1 (en) 2006-06-15
US20090209575A1 (en) 2009-08-20
WO2006063048A3 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
BRPI0518829A2 (pt) mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas
BRPI0818366A2 (pt) Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
CL2007002837A1 (es) Uso de fenitoina para tratar mucositis oral.
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
DE602005002066D1 (de) Vorrichtung zur Abschätzung des Hautzustandes
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
WO2007020103A3 (en) Novel use of peptide compounds for treating muscle pain
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
DK2151227T3 (da) Massagehoved og massageapparat, hvor dette hoved anvendes
BRPI0820519A2 (pt) intermediário para a síntese do análogo de halicondrina b e reação de dessulfonilação usada para o intermediário
DE602005019899D1 (de) System zur behandlung von ischämischem schlaganfall
ATE557021T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0509211A (pt) uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
DK1838318T3 (da) Anvendelse af oxycodon til behandling af visceral smerte
LTC1912640I2 (lt) HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
ES1061311Y (es) Aparato para prevenir y tratar el dolor de espalda
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014.

B25B Requested transfer of rights rejected

Owner name: AVIGEN, INC (US)